 The preclinical data on ORICs CD73 program were presented in the Advances in Cancer Drug Design and Discovery session in an oral presentation titled Orally Available Small Molecule CD73 Inhibitor Reverses Immunosuppression Through Blocking of Adenosine Production Abstract 1242, presentation 1037. Many cancers usurp the anti-inflammatory adenosine pathway to avoid detection by the immune system, thereby reducing the effectiveness of certain chemotherapy- and immunotherapy-based treatments. 